From virtual patients to digital twins in immuno-oncology: lessons learned from mechanistic quantitative systems pharmacology modeling

Hanwen Wang,Theinmozhi Arulraj,Alberto Ippolito,Aleksander S. Popel

2024-06-23

Abstract:Virtual patients and digital patients/twins are two similar concepts gaining increasing attention in health care with goals to accelerate drug development and improve patients' survival, but with their own limitations. Although methods have been proposed to generate virtual patient populations using mechanistic models, there are limited number of applications in immuno-oncology research. Furthermore, due to the stricter requirements of digital twins, they are often generated in a study-specific manner with models customized to particular clinical settings (e.g., treatment, cancer, and data types). Here, we discuss the challenges for virtual patient generation in immuno-oncology with our most recent experiences, initiatives to develop digital twins, and how research on these two concepts can inform each other.

Other Quantitative Biology

What problem does this paper attempt to address?

The paper attempts to address the challenges faced in generating Virtual Patients and Digital Twins in immuno-oncology. Specifically, the paper discusses the following aspects:

1. **Generation of Virtual Patients**:
- In immuno-oncology, the main challenges in generating virtual patients include:
- The mechanisms in the cancer-immune cycle are sometimes not fully understood, leading to their effects being represented through approximate methods (such as Hill functions) rather than detailed biochemical equations.
- Variables such as immune cell density and cytokine levels exhibit strong heterogeneity among individuals and across time and space.
- Many parameters and variables are difficult to measure or unavailable, or can only be scaled from animal models, or measured at only 1-3 time points throughout the entire clinical study.

2. **Development of Digital Twins**:
- Digital Twins are usually customized for specific clinical contexts (such as treatment, cancer type, and data type), thus requiring higher demands and more research-specific generation methods.
- The application of Digital Twins in personalized medicine emphasizes the correspondence with actual patients, requiring regular updates of model parameters to improve predictive accuracy.

3. **Interaction between Virtual Patients and Digital Twins**:
- Although Virtual Patients and Digital Twins are similar in concept, their goals differ. Virtual Patients are mainly used to predict the effects of new drugs or new therapy combinations in populations and assist in clinical trial design. Digital Twins, on the other hand, are used for personalized medicine, aiming to find the best treatment plan for each patient.
- The paper explores how to generate Digital Twins through Virtual Patients and how to use Digital Twins to improve the methods of generating Virtual Patients.

4. **Methods and Tools**:
- The steps for generating Virtual Patients are introduced, including selecting a subset of model parameters that represent inter-individual heterogeneity and randomly generating parameter values through Latin hypercube sampling.
- Utilizing multi-omics data from public databases (such as iAtlas) to generate Virtual Patients and ensuring that the generated Virtual Patients match the characteristics of real patients.
- Discussing how to generate new Virtual Patients through compressed latent parameterization methods to address the issue of sparse data.

In summary, the paper aims to share the authors' experiences in generating Virtual Patients and developing Digital Twins, discuss current challenges, and propose improved methods and tools to enhance the application of Virtual Patients and Digital Twins in immuno-oncology.